betibeglogene autotemcel + lovotibeglogene autotemcel

**Betibeglogene autotemcel + lovotibeglogene autotemcel** is a combination of two autologous hematopoietic stem cell-based gene therapies developed by bluebird bio for inherited hemoglobinopathies. Betibeglogene autotemcel (Zynteglo, beti-cel) uses a lentiviral vector (BB305 LVV) to transduce patient CD34+ stem cells ex vivo with a modified βA-T87Q-globin gene, enabling production of functional hemoglobin A (HbAT87Q) to correct β-globin deficiency in transfusion-dependent β-thalassemia (TDT). Lovotibeglogene autotemcel (Lyfgenia, lovo-cel) employs the same BB305 LVV to insert the βA-T87Q-globin gene, producing anti-sickling HbAT87Q in red blood cells to reduce vaso-occlusive events (VOEs) in sickle cell disease (SCD). Both are administered as one-time intravenous infusions after myeloablative conditioning; they were tested together in early-phase trials due to shared vector technology, offering potential transfusion independence (89% in TDT patients for beti-cel) and disease modification, though with risks like insertional oncogenesis and engraftment failure.[1][2][3][5][6][9][10]